- Cambrex has begun construction of a $30 million R&D facility at its Milan, Italy, site to expand analytical development and process R&D capabilities for small molecule development.
- The project, expected to be completed in the second half of 2027, also includes production plant upgrades and additional land acquisition to support future CDMO growth.
Cambrex has started construction of a new research and development facility at its Milan, Italy, site as part of a $30 million investment aimed at expanding its CDMO capabilities. The project will add advanced analytical development and process R&D capabilities while upgrading multiple production plants to support the development of increasingly complex small molecule therapies. The new facility is expected to be completed in the second half of 2027.
The expansion is intended to strengthen Cambrex’s ability to support pharmaceutical companies with small molecule development and contract manufacturing. To accommodate future growth and increasing demand for CDMO services, the company has also acquired additional land adjacent to the Milan site for future expansion.
The Cambrex Profarmaco Milano site, which celebrates its 80th anniversary this year, has supported pharmaceutical development and manufacturing for global customers over the past eight decades.
“Breaking ground on this new facility is a testament to the enduring legacy and expertise of our Milan team.”
Claudio Russolo, Chief Operating Officer at Cambrex
According to the company, the investment builds on its existing manufacturing and scientific capabilities while positioning the Milan site for future growth. Cambrex said the expanded R&D capabilities will help address the increasing complexity of today’s small molecule therapies.
